Five-Years Tigecycline Experience an Analysis of Real-Life Data

Aim: Tigecycline has been approved by the Food and DrugAdministration for the treatment of complicated intra-abdominalinfections, skin and soft tissue infections and community-acquiredpneumonia. In our study, we examined the efficacy of tigecycline inclinical practice and reported real life data from our hospital over aperiod of five years.Methods: The study was conducted between 2008 and 2013 onpatients who received tigecycline for longer than 48 hours in AnkaraTraining and Research Hospital. Clinical success was defined as clinicalrecovery and microbiological cure in patients who used tigecycline. Anyreason for discontinuation of tigecycline treatment was considered aclinical failure.Results: In our hospital, 320 patients were administered tigecyclinebetween 2008 and 2013. Tigecycline was mainly used for pneumoniaand skin and soft tissue infections. Tigecycline was used asmonotherapy in 174 patients (54.1%). The most frequently isolatedagent in tigecycline-treated patients was Acinetobacter baumannii(43.4%) followed by Enterococcus (6.9%). A change in treatmentwas not considered necessary in 243 (75.9%) patients who receivedtigecycline, while it was changed in 77 patients (24.1%).Conclusion: In conclusion, the use of tigecycline can be an effectivetreatment choice, either as monotherapy or as a combination antibiotictherapy.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Beş Yıllık Tigesiklin Deneyimi Gerçek Yaşam Verilerinin Bir Analizi

Öz:

Amaç: Komplike intraabdominal enfeksiyonlar, deri ve yumuşak doku enfeksiyonları ve toplum kökenli pnömoni tedavisi için Tigesiklin kullanımına Gıda ve İlaç Dairesi tarafından onay verilmiştir. Çalışmamızda; beş yıllık süreçte hastanemiz bünyesinde tigesiklin kullanımının klinik pratikteki yeri irdelenmiş ve gerçek yaşam verileri sunulmuştur. Yöntemler: Çalışma, 2008 ve 2013 yılları arasında, Ankara Eğitim ve Araştırma Hastanesi’nde, 48 saatten daha uzun süre ile tigesiklin kullanılan hastaların verileri retrospektif olarak değerlendirilmiştir. Klinik başarı, tigesiklini tek başına veya kombinasyonda kullanan hastaların tümünde klinik iyileşme ve mikrobiyolojik kür sağlanması olarak tanımlanmıştır. Herhangi bir nedenle tigesiklin tedavisinin kesilmesi klinik başarısızlık olarak tanımlanmıştır. Bulgular: Hastanemizde, 2008-2013 tarihleri arasında 320 hastaya tigesiklin kullanılmıştır. Tigesiklin en sık pnömoni ve deri-yumuşak doku enfeksiyonlarının tedavisinde kullanılmıştır. Hastaların 173’ünde (%54,1) monoterapi olarak kullanılmıştır. Hastalarda en sık izole edilen etken Acinetobacter baumannii olup (%43,4), ikinci sıklıkta Enterococcus izole edilmiştir (%6,9). Tedavi alan hastaların 243’ünde (%75,9) tedavi değişikliğine gerek görülmemiş olup 77 hastada (%24,1) tedavi değiştirilmiştir. Sonuç: Sonuç olarak, çoğul dirençli bakteri enfeksiyonlarının tedavisinde, monoterapi ya da kombinasyon olarak kullanıldığında tigesiklin bir seçenek olarak düşünülmelidir.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Bergeron J, Ammirati M, Danley D, et al. Glycylcyclines bind to the high affinity tetracycline ribosomal binding site and evade Tet(M)-and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996;40:2226-8.
Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000;20:S219-23.
Bauer G, Berens C, Projan SJ, et al. Comparison of tetracycline and tigecycline binding to ribosomes map- ped by dimethylsulphate and drug-directed FE2+ clea- vage of 16S rRNA. J Antimicrob Chemother 2004;53:592-9.
Hoellman DB, Pankuch GA, Jacobs MR, et al. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillinsusceptible and resistant pneumococci, Antimicrob Agents Chemother 2000;44:1085-8.
Murphy TM, Deitz JM, Petersen PJ, et al. Therapeutic efficacy of GAR-936, a novel glycylcycline in a rat model of experimental endocarditis, Antimicrob Agents Chemother 2000;44:3022-7.
Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004;64:63- 88.
Slover CM, Rodvold KA, Danziger LH. Tigecycline: an ovel broad-spectrum antimicrobial. Ann Pharmacother 2007;41:965-72.
Townsend ML, Pound MW, Drew RH. Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia. Infect Drug Resist 2011;4:77-86.
Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis 2013;75:331-6.
Conte JE Jr, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005;25:523-9.
Babinchak T, Ellis-Grosse E, Dartois N, et al. Tigecycline 301 Study Group; Tigecycline 306 Study Group: The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41:S354-67.
Ellis-Grosse EJ, Babinchak T, Dartois N, et al. Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group: The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin- aztreonam. Clin Infect Dis 2005;41:S341-53.
Europan Medical Agency. Tigecycline. Available from:s URL:http://www.ema.europa. eu/docs/enGB/document library/ EPAR Summary for the public/human/000644/ WC500044509. Accessed January 1, 2014.
Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 54:1699-709.
Curcio D, Vargas SW, Ugarte Ubiergo S, et al. Tigecycline treatment of critically ill patients: the LatinUser experience. Curr Clin Pharmacol 2011;6:18-25.
Philippe Montravers Herve´ Dupont Jean-Pierre Bedos Philippe Bret The Tigecycline Group. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting Intensive Care Med 2014;40:988-97.
Allen T, Griffin A, Julie A, et al. Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database. Diag Microb and Infec Dis 2013;77:273-7.
Kandemir O, Oztuna V, Colak M, et al. Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model. J Chemother 2008;20:53-7.
Seyman DH, Berk, Sepın ON, et al. Successful use of tigecycline for treatment of culture-negative pyogenic vertebral osteomyelitis. Infect Dis (Lond) 2015;47:783-8.
FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. Available from:s URL:http:// www.fda.gov/drugs/drugsafety/ucm369580.htm. Accesed April 4, 2016
Temocin F, Erdinc FS, Tulek N, et al. Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii. Braz J Microbiol 2015;46:1119-24.

APA	Temoçin F, TÜLEK N, HEKİMOĞLU Ş, ILGAR T, BULUT C, ERDINC F, ERTEM G, ATAMAN HATİPOĞLU Ç, KINIKLI S (2018). Five-Years Tigecycline Experience an Analysis of Real-Life Data. , 125 - 130. 10.4274/haseki.42713
Chicago	Temoçin Fatih,TÜLEK Necla Eren,HEKİMOĞLU Şirin,ILGAR Tuba,BULUT CEMAL,ERDINC Fatma Sebnem,ERTEM Günay Tuncer,ATAMAN HATİPOĞLU Çiğdem,KINIKLI SAMI Five-Years Tigecycline Experience an Analysis of Real-Life Data. (2018): 125 - 130. 10.4274/haseki.42713
MLA	Temoçin Fatih,TÜLEK Necla Eren,HEKİMOĞLU Şirin,ILGAR Tuba,BULUT CEMAL,ERDINC Fatma Sebnem,ERTEM Günay Tuncer,ATAMAN HATİPOĞLU Çiğdem,KINIKLI SAMI Five-Years Tigecycline Experience an Analysis of Real-Life Data. , 2018, ss.125 - 130. 10.4274/haseki.42713
AMA	Temoçin F,TÜLEK N,HEKİMOĞLU Ş,ILGAR T,BULUT C,ERDINC F,ERTEM G,ATAMAN HATİPOĞLU Ç,KINIKLI S Five-Years Tigecycline Experience an Analysis of Real-Life Data. . 2018; 125 - 130. 10.4274/haseki.42713
Vancouver	Temoçin F,TÜLEK N,HEKİMOĞLU Ş,ILGAR T,BULUT C,ERDINC F,ERTEM G,ATAMAN HATİPOĞLU Ç,KINIKLI S Five-Years Tigecycline Experience an Analysis of Real-Life Data. . 2018; 125 - 130. 10.4274/haseki.42713
IEEE	Temoçin F,TÜLEK N,HEKİMOĞLU Ş,ILGAR T,BULUT C,ERDINC F,ERTEM G,ATAMAN HATİPOĞLU Ç,KINIKLI S "Five-Years Tigecycline Experience an Analysis of Real-Life Data." , ss.125 - 130, 2018. 10.4274/haseki.42713
ISNAD	Temoçin, Fatih vd. "Five-Years Tigecycline Experience an Analysis of Real-Life Data". (2018), 125-130. https://doi.org/10.4274/haseki.42713

APA	Temoçin F, TÜLEK N, HEKİMOĞLU Ş, ILGAR T, BULUT C, ERDINC F, ERTEM G, ATAMAN HATİPOĞLU Ç, KINIKLI S (2018). Five-Years Tigecycline Experience an Analysis of Real-Life Data. Haseki Tıp Bülteni, 56(2), 125 - 130. 10.4274/haseki.42713
Chicago	Temoçin Fatih,TÜLEK Necla Eren,HEKİMOĞLU Şirin,ILGAR Tuba,BULUT CEMAL,ERDINC Fatma Sebnem,ERTEM Günay Tuncer,ATAMAN HATİPOĞLU Çiğdem,KINIKLI SAMI Five-Years Tigecycline Experience an Analysis of Real-Life Data. Haseki Tıp Bülteni 56, no.2 (2018): 125 - 130. 10.4274/haseki.42713
MLA	Temoçin Fatih,TÜLEK Necla Eren,HEKİMOĞLU Şirin,ILGAR Tuba,BULUT CEMAL,ERDINC Fatma Sebnem,ERTEM Günay Tuncer,ATAMAN HATİPOĞLU Çiğdem,KINIKLI SAMI Five-Years Tigecycline Experience an Analysis of Real-Life Data. Haseki Tıp Bülteni, vol.56, no.2, 2018, ss.125 - 130. 10.4274/haseki.42713
AMA	Temoçin F,TÜLEK N,HEKİMOĞLU Ş,ILGAR T,BULUT C,ERDINC F,ERTEM G,ATAMAN HATİPOĞLU Ç,KINIKLI S Five-Years Tigecycline Experience an Analysis of Real-Life Data. Haseki Tıp Bülteni. 2018; 56(2): 125 - 130. 10.4274/haseki.42713
Vancouver	Temoçin F,TÜLEK N,HEKİMOĞLU Ş,ILGAR T,BULUT C,ERDINC F,ERTEM G,ATAMAN HATİPOĞLU Ç,KINIKLI S Five-Years Tigecycline Experience an Analysis of Real-Life Data. Haseki Tıp Bülteni. 2018; 56(2): 125 - 130. 10.4274/haseki.42713
IEEE	Temoçin F,TÜLEK N,HEKİMOĞLU Ş,ILGAR T,BULUT C,ERDINC F,ERTEM G,ATAMAN HATİPOĞLU Ç,KINIKLI S "Five-Years Tigecycline Experience an Analysis of Real-Life Data." Haseki Tıp Bülteni, 56, ss.125 - 130, 2018. 10.4274/haseki.42713
ISNAD	Temoçin, Fatih vd. "Five-Years Tigecycline Experience an Analysis of Real-Life Data". Haseki Tıp Bülteni 56/2 (2018), 125-130. https://doi.org/10.4274/haseki.42713